Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,319 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,657 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06280196 | A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC | terminated | Phase 3 | 162 | Bio-Thera SolutionsINDUSTRY | 1 | Dec 2, 2025 | clinicaltrials |
| NCT01546571 | Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients(MAVIS) | terminated | Phase 3 | 504 | Polynoma LLCINDUSTRY | 2 | Oct 24, 2025 | clinicaltrials |
| NCT04551066 | To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) | terminated | Phase 3 | 252 | Incyte CorporationINDUSTRY | 17 | Oct 21, 2025 | clinicaltrials |
| NCT04459715 | A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX) | terminated | Phase 3 | 730 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 26 | Oct 8, 2025 | clinicaltrials |
| NCT04458909 | Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer | terminated | Phase 3 | 15 | National Cancer Institute (NCI)NIH | 4 | Oct 3, 2025 | clinicaltrials |
| NCT04551053 | To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) | terminated | Phase 3 | 177 | Incyte CorporationINDUSTRY | 19 | Oct 2, 2025 | clinicaltrials |
| NCT04619433 | A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC. | terminated | Phase 3 | 48 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT05870748 | REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 | terminated | Phase 2 / Phase 3 | 600 | Sutro Biopharma, Inc.INDUSTRY | 7 | Sep 23, 2025 | clinicaltrials |
| NCT02967692 | A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma(COMBI-i) | terminated | Phase 3 | 568 | Novartis PharmaceuticalsINDUSTRY | 29 | Sep 18, 2025 | clinicaltrials |
| NCT03149575 | VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM(STAR-3) | terminated | Phase 3 | 2 | DelMar Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT05092360 | Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)(ARTISTRY-7) | terminated | Phase 3 | 456 | Mural Oncology, IncINDUSTRY | 14 | Aug 28, 2025 | clinicaltrials |
| NCT02363400 | A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA | terminated | Phase 3 | 10 | National Health Research Institutes, TaiwanOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT04159155 | A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer(CAN-STAMP) | terminated | Phase 2 / Phase 3 | 11 | University Health Network, TorontoOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT03194646 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 6) | terminated | Phase 3 | 1,272 | BayerINDUSTRY | 13 | Jul 28, 2025 | clinicaltrials |
| NCT00087776 | Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma | terminated | Phase 3 | 393 | American Regent, Inc.INDUSTRY | 1 | Jul 23, 2025 | clinicaltrials |
| NCT04921358 | Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | terminated | Phase 3 | 377 | BeiGeneINDUSTRY | 2 | Jun 29, 2025 | clinicaltrials |
| NCT06643117 | Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda as add-on to Chemotherapy in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC)(Lotus) | terminated | Phase 3 | 25 | Formycon AGINDUSTRY | 3 | Jun 26, 2025 | clinicaltrials |
| NCT05269355 | A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)(SUNRISELMS) | terminated | Phase 2 / Phase 3 | 359 | PTC TherapeuticsINDUSTRY | 12 | Jun 13, 2025 | clinicaltrials |
| NCT06108739 | ATG Plus Low-dose PT-Cy for GVHD Prevention | terminated | Phase 3 | 66 | Peking University People's HospitalOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT04427072 | Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation(GeoMETry-III) | terminated | Phase 3 | 22 | Novartis PharmaceuticalsINDUSTRY | 18 | May 16, 2025 | clinicaltrials |
| NCT02807181 | SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma(SIRCCA) | terminated | Phase 2 / Phase 3 | 89 | Sirtex MedicalINDUSTRY | 8 | May 9, 2025 | clinicaltrials |
| NCT05930938 | Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer(XXL_2022-01) | terminated | Phase 3 | 19 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | May 9, 2025 | clinicaltrials |
| NCT03016130 | Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101) | terminated | Phase 3 | 217 | University of FloridaOTHER | 1 | Apr 7, 2025 | clinicaltrials |
| NCT05079230 | Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia(ENHANCE-3) | terminated | Phase 3 | 378 | Gilead SciencesINDUSTRY | 20 | Apr 4, 2025 | clinicaltrials |
| NCT04786964 | Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC(CONTERNO) | terminated | Phase 3 | 25 | Checkpoint Therapeutics, Inc.INDUSTRY | 8 | Apr 2, 2025 | clinicaltrials |
| NCT02641639 | FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer | terminated | Phase 2 / Phase 3 | 70 | Mateon TherapeuticsINDUSTRY | 3 | Mar 24, 2025 | clinicaltrials |
| NCT00448240 | Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer | terminated | Phase 2 / Phase 3 | 6 | Henry Ford Health SystemOTHER | 0 | Mar 18, 2025 | clinicaltrials |
| NCT03746054 | Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality(PALERMO) | terminated | Phase 3 | 80 | University Hospital, AngersOTHER_GOV | 1 | Mar 17, 2025 | clinicaltrials |
| NCT04316013 | Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial | terminated | Phase 3 | 254 | Peter MacCallum Cancer Centre, AustraliaOTHER | 3 | Mar 14, 2025 | clinicaltrials |
| NCT04421547 | Efficacy of Letrozole in Recurrent Ovarian Cancer(MITO32) | terminated | Phase 3 | 86 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT04901988 | Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION(DETECTION) | terminated | Phase 2 / Phase 3 | 8 | The Christie NHS Foundation TrustOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT04709380 | Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT | terminated | Phase 3 | 36 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT03013946 | Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy(PREPARE) | terminated | Phase 3 | 121 | AIO-Studien-gGmbHOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT02231164 | LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research | terminated | Phase 3 | 12 | Boehringer IngelheimINDUSTRY | 3 | Feb 13, 2025 | clinicaltrials |
| NCT05664217 | NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma | terminated | Phase 2 / Phase 3 | 15 | Nektar TherapeuticsINDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
| NCT04778397 | Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated(ENHANCE-2) | terminated | Phase 3 | 258 | Gilead SciencesINDUSTRY | 15 | Feb 5, 2025 | clinicaltrials |
| NCT05181540 | A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation(E-CELERATE) | terminated | Phase 3 | 130 | Angiocrine BioscienceINDUSTRY | 1 | Feb 4, 2025 | clinicaltrials |
| NCT02887521 | Pulmonary Rehabilitation Before Lung Cancer Resection | terminated | Phase 3 | 9 | Alliance for Clinical Trials in OncologyOTHER | 2 | Feb 3, 2025 | clinicaltrials |
| NCT04979442 | Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma(MANTRA) | terminated | Phase 3 | 175 | Rain Oncology IncINDUSTRY | 15 | Jan 14, 2025 | clinicaltrials |
| NCT02612311 | Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia(UNITY-CLL) | terminated | Phase 3 | 603 | TG Therapeutics, Inc.INDUSTRY | 7 | Dec 13, 2024 | clinicaltrials |
| NCT02626455 | Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)(CHRONOS-4) | terminated | Phase 3 | 551 | BayerINDUSTRY | 35 | Dec 11, 2024 | clinicaltrials |
| NCT02588261 | A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations(SOLAR) | terminated | Phase 3 | 530 | Astellas Pharma Global Development, Inc.INDUSTRY | 23 | Dec 10, 2024 | clinicaltrials |
| NCT04745832 | Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) | terminated | Phase 3 | 82 | MEI Pharma, Inc.INDUSTRY | 19 | Nov 4, 2024 | clinicaltrials |
| NCT03240523 | A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 5) | terminated | Phase 3 | 766 | BayerINDUSTRY | 23 | Oct 18, 2024 | clinicaltrials |
| NCT03447769 | Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A(Canopy-A) | terminated | Phase 3 | 1,382 | Novartis PharmaceuticalsINDUSTRY | 41 | Oct 9, 2024 | clinicaltrials |
| NCT03452137 | A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck(IMvoke010) | terminated | Phase 3 | 406 | Hoffmann-La RocheINDUSTRY | 23 | Oct 9, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Dec 2, 2025source: clinicaltrials